Brazil Pharmaceuticals & Healthcare Q1 2019
The Brazilian pharmaceutical market has markedly declined in recent years due to the country's recession, limitingmultinational drugmaker appetite. Despite a slight recovery in 2017, Brazil will remain a highly challenging market. A restriction onpublic healthcare expenditure will place additional pressures on medicine prices while schemes to control prices and boost localcapacity will further dissuade foreign investment. Of the four BRICs markets, Brazil represents the worst growth prospect, althoughwe highlight that the implementation of health technology assessment indicates an improving regulatory outlook for drugmakers.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook